JosephSouferMD

Endocrinology • Waterbury, CT

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. Soufer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Soufer's full profile

Already have an account?

Office
500 Chase Pkwy
3rd Fl
Waterbury, CT 06708
Phone+1 203-574-2930

Fax+1 203-574-2933

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Endocrinology, Diabetes, and Metabolism, 1980 - 1982
Yale-New Haven Medical CenterResidency, Internal Medicine, 1977 - 1980
Universite Libre de Bruxelles Faculty of MedicineClass of 1977

Certifications & Licensure

NY State Medical License 1980 - 2026
CT State Medical License 1979 - 2025
American Board of Internal Medicine Internal Medicine

Clinical Trials

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Start of enrollment: 2010 Mar 01
Completed
Phase 3
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
Completed
Phase 3
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
Safety and Effectiveness Study of a Non-Crosslinked HA Alkylamide HYADD(TM) 4 Hydrogel for Osteoarthritis of the Knee Start of enrollment: 2014 Jun 01
Unknown status
Not Applicable
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy Start of enrollment: 2016 Dec 01
Completed
Phase 2
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2017 May 24
Completed
Phase 2
Join now to see all

Press Mentions

Tamer Ghaly, MD, a Pain Management Specialist with Valley Orthopedic SpecialistsJuly 2nd, 2021